Nuvectis Pharma reported a net loss of $6.1 million for Q1 2026, slightly higher than the previous year, while continuing patient enrollment in its NXP900 Phase 1b clinical trial for cancer treatment. The company highlighted promising preclinical data showing synergy of NXP900 combined with sotorasib in lung cancer models. With $25.1 million in cash, Nuvectis expects preliminary clinical data this summer and remains focused on advancing its oncology drug development with financial discipline.
Man Group PLC has publicly disclosed holding a 1.63% interest in Senior Plc through cash-settled equity swaps as of July 24, 2026. This disclosure is made under Rule 8.3 of the UK Takeover Code, indicating a significant stake in the company. The posi...
The global blowing agent market, valued at $1.79 billion in 2025, is projected to reach $2.94 billion by 2035 with a CAGR of 5.41%. Growth is fueled by increasing demand for low-global warming potential (GWP) insulation solutions, stricter environmen...
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to repurchase shares worth up to DKK 3.1 billion by February 2027. The company has repurchased 4,432,353 shares at an average price of DKK 250.27, totaling abo...
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed public dealings involving the purchase and sale of 52,929 ordinary shares on July 24, 2026. The trades occurred within a price range of 941 to 956.75 per share. There w...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group plc, disclosed public dealings in the company's ordinary shares on July 24, 2026. The bank purchased 2,326,617 shares at prices between 280 and 280.5 pence and ...
